Replimune Group, Inc.
NMS: REPLLive Quote
📈 ZcoreAI Score
Our AI model analyzes Replimune Group, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get REPL Z-Score →About Replimune Group, Inc.
Healthcare
Biotechnology
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
📊 Fundamental Analysis
Replimune Group, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -90.9%, which indicates that capital utilization is currently under pressure.
At a current price of $4.76, REPL currently trades near the bottom of its 52-week range (20%), indicating potential value or weakness (Range: $2.68 - $13.24).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$393.05M
Trailing P/E
--
Forward P/E
-2.51
Beta (5Y)
0.74
52W High
$13.24
52W Low
$2.68
Avg Volume
1.84M
Day High
Day Low